{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:16:45Z","timestamp":1793143005387,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","ijaaonline.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.ijantimicag.2015.12.018","type":"journal-article","created":{"date-parts":[[2016,1,30]],"date-time":"2016-01-30T02:22:25Z","timestamp":1454120545000},"page":"202-209","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Optimal dosing regimen of biapenem in Chinese patients with lower respiratory tract infections based on population pharmacokinetic\/pharmacodynamic modelling and Monte Carlo simulation"],"prefix":"10.1016","volume":"47","author":[{"given":"Jing","family":"Dong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuancheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunfeng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xijing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2015.12.018_bib0180","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1128\/AAC.36.2.481","article-title":"Renal dehydropeptidase-I stability of LJC 10,627, a new carbapenem antibiotic","volume":"36","author":"Hikida","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.12.018_bib0185","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/jac\/35.1.75","article-title":"Biochemical comparison of imipenem, meropenem and biapenem: permeability, binding to penicillin-binding proteins, and stability to hydrolysis by \u03b2-lactamases","volume":"35","author":"Yang","year":"1995","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2015.12.018_bib0190","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.2165\/00003495-200262150-00005","article-title":"Biapenem","volume":"62","author":"Perry","year":"2002","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2015.12.018_bib0195","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1128\/AAC.45.1.13-22.2001","article-title":"Use of preclinical data for selection of a phase II\/III dose for evernimicin and identification of a preclinical MIC breakpoint","volume":"45","author":"Drusano","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.12.018_bib0200","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1592\/phco.23.3.291.32110","article-title":"Integration of population pharmacokinetics, a pharmacodynamic target, and microbiologic surveillance data to generate a rational empiric dosing strategy for cefepime against Pseudomonas aeruginosa","volume":"23","author":"Tam","year":"2003","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2015.12.018_bib0205","series-title":"Performance standards for antimicrobial susceptibility testing; twenty-third informational supplement. Document M100-S23","author":"Clinical and Laboratory Standards Institute","year":"2014"},{"key":"10.1016\/j.ijantimicag.2015.12.018_bib0210","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1159\/000152459","article-title":"Pharmacokinetic\u2013pharmacodynamic target attainment analysis of biapenem in adult patients: a dosing strategy","volume":"54","author":"Ikawa","year":"2008","journal-title":"Chemotherapy"},{"key":"10.1016\/j.ijantimicag.2015.12.018_bib0215","doi-asserted-by":"crossref","first-page":"5609","DOI":"10.1128\/AAC.00497-11","article-title":"Clinical pharmacokinetics of meropenem and biapenem in bile and dosing considerations for biliary tract infections based on site-specific pharmacodynamic target attainment","volume":"55","author":"Ikawa","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.12.018_bib0220","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.2165\/00003495-200767070-00006","article-title":"Comparative review of the carbapenems","volume":"67","author":"Zhanel","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2015.12.018_bib0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/516284","article-title":"Pharmacokinetic\/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men","volume":"26","author":"Craig","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2015.12.018_bib0230","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1086\/344653","article-title":"Prevention of resistance: a goal for dose selection for antimicrobial agents","volume":"36","author":"Drusano","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2015.12.018_bib0235","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s10156-011-0271-9","article-title":"Optimal treatment schedule of meropenem for adult patients with febrile neutropenia based on pharmacokinetic\u2013pharmacodynamic analysis","volume":"17","author":"Ohata","year":"2011","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.ijantimicag.2015.12.018_bib0240","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1093\/jac\/dku429","article-title":"Dosing regimen of meropenem for adults with severe burns: a population pharmacokinetic study with Monte Carlo simulations","volume":"70","author":"Ramon-Lopez","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2015.12.018_bib0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"10.1016\/j.ijantimicag.2015.12.018_bib0250","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1055\/s-0033-1341498","article-title":"Tolerability and pharmacokinetics of biapenem following single and multiple intravenous administrations in healthy Chinese subjects: an open-label, randomized, single-center study","volume":"63","author":"Liu","year":"2013","journal-title":"Drug Res (Stuttg)"},{"key":"10.1016\/j.ijantimicag.2015.12.018_bib0255","unstructured":"Venables WN, Smith DM. R Development Core Team. R Version 2.1.4.0. The R Foundation for Statistical Computing. http:\/\/www.r-project.org [accessed May 2014]."},{"key":"10.1016\/j.ijantimicag.2015.12.018_bib0260","doi-asserted-by":"crossref","first-page":"E27","DOI":"10.1208\/ps040427","article-title":"Comparison of stepwise covariate model building strategies in population pharmacokinetic\u2013pharmacodynamic analysis","volume":"4","author":"W\u00e4hlby","year":"2002","journal-title":"AAPS PharmSci"},{"key":"10.1016\/j.ijantimicag.2015.12.018_bib0265","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","article-title":"Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models","volume":"13","author":"Bergstrand","year":"2011","journal-title":"AAPS J"},{"key":"10.1016\/j.ijantimicag.2015.12.018_bib0270","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/jac\/dki079","article-title":"Standardization of pharmacokinetic\/pharmacodynamic (PK\/PD) terminology for anti-infective drugs: an update","volume":"55","author":"Mouton","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2015.12.018_bib0275","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.diagmicrobio.2007.01.004","article-title":"Reevaluation of current susceptibility breakpoints for Gram-negative rods based on pharmacodynamic assessment","volume":"58","author":"DeRyke","year":"2007","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2015.12.018_bib0280","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ijantimicag.2012.09.007","article-title":"Pharmacodynamic profiling of doripenem, imipenem and meropenem against prevalent Gram-negative organisms in the Asia-Pacific region","volume":"41","author":"Kiratisin","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2015.12.018_bib0285","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ijantimicag.2010.10.024","article-title":"Pharmacodynamic profiling of intravenous antibiotics against prevalent Gram-negative organisms across the globe: the PASSPORT Program\u2014Asia-Pacific Region","volume":"37","author":"Roberts","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2015.12.018_bib0290","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.1365-2710.2008.00908.x","article-title":"Population pharmacokinetics and pharmacodynamics of biapenem in paediatric patients","volume":"33","author":"Ikawa","year":"2008","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.ijantimicag.2015.12.018_bib0295","first-page":"70","article-title":"Phase 1 study of L-627, biapenem, a new parenteral carbapenem antibiotic","volume":"31","author":"Nakashima","year":"1993","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"10.1016\/j.ijantimicag.2015.12.018_bib0300","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.rmed.2005.05.009","article-title":"Pharmacokinetic study of pleural fluid penetration of carbapenem antibiotic agents in chemical pleurisy","volume":"100","author":"Niwa","year":"2006","journal-title":"Respir Med"},{"key":"10.1016\/j.ijantimicag.2015.12.018_bib0305","first-page":"769","article-title":"Pharmacokinetic study of biapenem","volume":"44","author":"Tarao","year":"1996","journal-title":"Jpn J Chemother"},{"key":"10.1016\/j.ijantimicag.2015.12.018_bib0310","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.ijantimicag.2008.03.011","article-title":"Pharmacodynamic evaluation of biapenem in peritoneal fluid using population pharmacokinetic modelling and Monte Carlo simulation","volume":"32","author":"Ikawa","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2015.12.018_bib0315","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1055\/s-0031-1296189","article-title":"Improved RP-HPLC method to determine biapenem in human plasma\/urine and its application to a pharmacokinetic study","volume":"61","author":"Zhao","year":"2011","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.ijantimicag.2015.12.018_bib0320","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1345\/aph.1E271","article-title":"Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia","volume":"39","author":"Ariano","year":"2005","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ijantimicag.2015.12.018_bib0325","doi-asserted-by":"crossref","first-page":"903","DOI":"10.2165\/11595960-000000000-00000","article-title":"Pharmacokinetics and pharmacodynamics of meropenem in elderly Chinese with lower respiratory tract infections: population pharmacokinetics analysis using nonlinear mixed-effects modelling and clinical pharmacodynamics study","volume":"28","author":"Zhou","year":"2011","journal-title":"Drugs Aging"},{"key":"10.1016\/j.ijantimicag.2015.12.018_bib0330","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ijantimicag.2007.12.009","article-title":"Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections","volume":"31","author":"McKinnon","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2015.12.018_bib0335","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1128\/AAC.01578-08","article-title":"Comparison of the pharmacodynamics of biapenem in bronchial epithelial lining fluid in healthy volunteers given half-hour and three-hour intravenous infusions","volume":"53","author":"Kikuchi","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.12.018_bib0340","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.jpba.2009.02.002","article-title":"The stability of biapenem and structural identification of impurities in aqueous solution","volume":"49","author":"Xia","year":"2009","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.ijantimicag.2015.12.018_bib0345","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1177\/0300060515587577","article-title":"Multicentre investigation of pathogenic bacteria and antibiotic resistance genes in Chinese patients with acute exacerbation of chronic obstructive pulmonary disease","volume":"43","author":"Ma","year":"2015","journal-title":"J Int Med Res"},{"key":"10.1016\/j.ijantimicag.2015.12.018_bib0350","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1007\/s10156-013-0605-x","article-title":"Efficacy and safety of piperacillin\/tazobactam versus biapenem in late elderly patients with nursing- and healthcare-associated pneumonia","volume":"19","author":"Karino","year":"2013","journal-title":"J Infect Chemother"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857916000340?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857916000340?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,15]],"date-time":"2018-09-15T17:26:14Z","timestamp":1537032374000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857916000340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["S0924857916000340"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2015.12.018","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimal dosing regimen of biapenem in Chinese patients with lower respiratory tract infections based on population pharmacokinetic\/pharmacodynamic modelling and Monte Carlo simulation","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2015.12.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}